Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 5 publications
references
References 7 publications
0
11
0
Order By: Relevance
“…20 No pharmacokinetic assays were performed. 20 To our knowledge, successful treatment of a patient with PCNSL using ibrutinib while on hemodialysis has not been previously reported. Ibrutinib concentrations in CSF were markedly lower in CA1 on the hemodialysis day compared to the non-dialysis day, although still detectable.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…20 No pharmacokinetic assays were performed. 20 To our knowledge, successful treatment of a patient with PCNSL using ibrutinib while on hemodialysis has not been previously reported. Ibrutinib concentrations in CSF were markedly lower in CA1 on the hemodialysis day compared to the non-dialysis day, although still detectable.…”
Section: Discussionmentioning
confidence: 99%
“…Although ibrutinib has minimal renal clearance, information on the safety and efficacy of ibrutinib therapy in patients with lymphoma requiring hemodialysis is limited to a case report of a patient with systemic mantle cell lymphoma 20 . No pharmacokinetic assays were performed 20 . To our knowledge, successful treatment of a patient with PCNSL using ibrutinib while on hemodialysis has not been previously reported.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Case reports and case series reporting on actual treatment of NHL patients on HD are shown in Table 1 (rituximab, CVP, and CHOP), 2,3,6,10‐35 Table 2 (various other regimens), 10,19,25,34‐51 and Table 3 (stem cell transplantation), 34,52‐54 and are discussed below. Recommendations on individual drug administrations are summarized in Table 4 3‐5,9‐11,19,25,38,39,43‐46,55‐60 .…”
Section: Individual Treatment Methodsmentioning
confidence: 99%
“…Case reports and case series reporting on actual treatment of NHL patients on HD are shown in Table 1 (rituximab, CVP, and CHOP), 2,3,6,10‐35 Table 2 (various other regimens), 10,19,25,34‐51 and Table 3 (stem cell transplantation), 34,52‐54 and are discussed below. Recommendations on individual drug administrations are summarized in Table 4 3‐5,9‐11,19,25,38,39,43‐46,55‐60 . Despite the possible bias of case reports favoring cases with good outcomes, overall the rates of adverse events are high and outcomes of the extracted cases are dismal compared to their counterparts not on HD.…”
Section: Individual Treatment Methodsmentioning
confidence: 99%